Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Cash from Operations: 2016-2025

Historic Cash from Operations for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $28.1 million.

  • Akebia Therapeutics' Cash from Operations rose 519.79% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 184.15%. This contributed to the annual value of -$40.7 million for FY2024, which is 73.88% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Cash from Operations is $28.1 million, which was up 25.78% from $22.3 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Cash from Operations registered a high of $33.8 million during Q3 2022, and its lowest value of -$70.7 million during Q1 2021.
  • Its 3-year average for Cash from Operations is -$2.5 million, with a median of -$6.7 million in 2024.
  • In the last 5 years, Akebia Therapeutics' Cash from Operations plummeted by 377.38% in 2024 and then skyrocketed by 519.79% in 2025.
  • Akebia Therapeutics' Cash from Operations (Quarterly) stood at -$62.8 million in 2021, then increased by 12.94% to -$54.7 million in 2022, then skyrocketed by 95.78% to -$2.3 million in 2023, then plummeted by 93.50% to -$4.5 million in 2024, then skyrocketed by 519.79% to $28.1 million in 2025.
  • Its Cash from Operations stands at $28.1 million for Q3 2025, versus $22.3 million for Q2 2025 and -$13.6 million for Q1 2025.